{
  "content": "Abstract\nBackground:\nAmiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin.\nObjectives:\nThis study sought to examine the association of major thrombotic clinical events and bleeding with the use of amiodarone in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.\nMethods:",
  "source": "https://www.jacc.org/doi/10.1016/j.jacc.2014.07.967",
  "chunk_id": "4ec8decb-8e99-4c99-ab18-077e84ec4eee",
  "similarity_score": 0.2889508008956909,
  "query": "amiodarone pharmacokinetics drug interactions CYP450 beta-blockers metabolism clearance atrial fibrillation dosing",
  "rank": 23,
  "title": "Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial",
  "authors": "Greg Flaker, Renato D. Lopes, Elaine Hylek, Daniel M. Wojdyla, Laine Thomas, Sana M. Al-Khatib, Renee M. Sullivan, Stefan H. Hohnloser, David Garcia, Michael Hanna, John Amerena, Veli-Pekka Harjola, Paul Dorian, Alvaro Avezum, Matyas Keltai, Lars Wallentin, Christopher B. Granger",
  "year": "2014",
  "journal": "JACC",
  "reference": "Flaker, G., Lopes, R. D., Hylek, E., Wojdyla, D. M., Thomas, L., Al-Khatib, S. M., Sullivan, R. M., Hohnloser, S. H., Garcia, D., Hanna, M., Amerena, J., Harjola, V.-P., Dorian, P., Avezum, A., Keltai, M., Wallentin, L., & Granger, C. B. (2014). Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: Insights from the ARISTOTLE trial. JACC, 64(15), 556-575.",
  "doi": "Not available",
  "chunk_index": 5,
  "total_chunks": 111,
  "retrieved_at": "2025-07-24T21:58:09.739169"
}